New drug for fatty liver disease takes first step in human testing
NCT ID NCT06308874
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested the safety and tolerability of a single dose of J2H-1702 in 16 healthy women. The drug is being developed for non-alcoholic steatohepatitis (NASH), a serious liver condition. Researchers measured how the body processes the drug and its effects, but this study does not yet test if it works against the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- J2H-1702
- What this could lead to
- If successful, this could lead to further studies testing J2H-1702 as a potential treatment for non-alcoholic steatohepatitis (NASH), a liver disease.
- What could go wrong
- This is a very early Phase 1 trial with only 16 healthy women, not patients. It only tests safety and drug levels, not whether it works for NASH. Many drugs fail at this stage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC STEATOHEPATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
J2H Biotech
Suwon, Gyeonggi-do, 16684, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new MRI technique could see inside the Liver's metabolism without a biopsy
- Blood test and AI could spot liver cancer early, saving lives
- Painless liver check: could a quick scan replace the needle?
- Computer nudge boosts liver referrals
- Healthy volunteers needed to test safety of experimental NASH drug
- Can genes predict liver cancer? new study seeks answers